Ginsenosides: potential therapeutic agents against hepatic fibrosis Authors: Zhengzheng Wu, Yi Liu Published: 2026 ABSTRACT Hepatic fibrosis, for which no effective pharmacological interventions currently exist, is characterized by progressive scarring and architectural distortion. The pathogenesis involves excessive accumulation of extracellular matrix components, predominantly synthesized by activated hepatic stellate cells (HSCs). HSCs can be activated by inflammatory signals and injured hepatocytes, processes linked to intestinal microbiota dysbiosis. Therefore, HSCs and associated pathways constitute promising therapeutic targets for antifibrotic strategies. Recent evidence suggests that ginsenosides, principal bioactive constituents of Panax ginseng, demonstrate hepatoprotective and antifibrotic properties. Ginsenosides are structurally classified into dammarane-type, ocotillol-type, and oleanane-type saponins, showing favorable safety profiles. Their pharmacological activity is critically dependent on structural features, including the quantity, type, and glycosylation positions of sugar moieties, as well as the stereochemical configuration at the C-20 position. The antifibrotic mechanisms of ginsenosides encompass multiple pathways: suppression of HSC activation, induction of HSC death, amelioration of hepatocellular injury, attenuation of inflammatory responses, and modulation of intestinal microbiota composition. This review aims to evaluate ginsenosides as potential therapeutic agents for hepatic fibrosis and to establish a theoretical framework for their clinical translation in the management of this condition. Introduction Hepatic fibrosis, a characteristic pathological feature common to diverse chronic liver diseases, is defined by persistent inflammation and pathological accumulation of extracellular matrix (ECM) resulting from chronic and recurrent hepatic injury [1]. Etiological factors encompass viral hepatitis, such as infections caused by the hepatitis B virus (HBV) and hepatitis C virus (HCV), chronic ethanol exposure, drug-induced hepatotoxicity, autoimmunity-mediated liver disease, and cholestatic disorders, among others. Upon hepatic injury, damaged hepatocytes release various cytokines that trigger immune cell recruitment and activation [2]. Consequently, inflammatory mediators released from injured hepatocytes and activated immune cells drive the activation of quiescent hepatic stellate cells (HSCs). These cells subsequently differentiate into a myofibroblast-like phenotype, which constitutes the primary source of fibrosis-promoting extracellular matrix (ECM) components [3]. Excessive ECM accumulation disrupts hepatic architecture and function, ultimately resulting in hepatic fibrosis. Affecting millions globally, hepatic fibrosis represents a major public health burden. This condition may advance to cirrhosis and has the potential to eventually develop into hepatocellular carcinoma [4]. Currently, resmetirom remains the only FDA-approved pharmacological agent specifically indicated for hepatic fibrosis; however, its therapeutic application is confined to individuals diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) and shows only modest clinical efficacy [5,6]. Consequently, the urgent requirement is the identification and development of innovative therapeutics capable of effectively preventing or reversing fibrotic progression. As a medicinally valuable botanical species, ginseng has been extensively investigated for therapeutic applications across diverse disease conditions due to its established effectiveness and a well-tolerated profile. Ginseng is defined as a perennial herb from the Araliaceae family with a rhizomatous growth form. Its chemical profile encompasses a variety of bioactive compounds, notably ginsenosides, along with phenolics, polysaccharides, and phytosterols. Among these phytochemical components, ginsenosides represent the principal bioactive constituents that account for most of ginseng's pharmacological activities. The pharmacological activities of ginsenosides have been demonstrated in multiple pathological conditions, including depression, cancer, fibrosis, and inflammatory diseases [7,8]. Ginsenosides have garnered increasing attention due to their antifibrotic properties mediated by multiple mechanisms. For instance, ginsenosides Rg3 and Rh2 suppress hepatic fibrosis progression by inducing ferroptosis in HSCs [9,10]. Ginsenoside AD-2 inhibits HSC activation, ameliorating hepatic fibrosis [11]. In addition, ginsenosides show favorable safety profiles, with mild and reversible toxicity [12]. Given the complex pathophysiology of hepatic fibrosis, single-target therapeutic agents demonstrate limited efficacy, which partially explains the limitation of the existing FDA-approved therapy, with modest efficacy and restriction to patients with MASLD. The multi-target pharmacological characteristics of ginsenosides position them as promising therapeutic candidates for hepatic fibrosis. Furthermore, as naturally derived pharmaceutical compounds, ginsenosides show favorable safety profiles with minimal adverse effects and are suitable for chronic administration, further reinforcing their potential as antifibrotic agents. The current review offers a comprehensive summary of ginsenosides, including their chemical structures, classification, structure-activity relationship, and safety profiles, as well as the molecular mechanisms underlying their antifibrotic effects in liver fibrosis. These mechanisms encompass the inhibition of HSC activation, induction of HSC death, attenuation of hepatocyte injury, modulation of inflammatory responses, and regulation of intestinal microbiota. Furthermore, we systematically summarize the therapeutic effects of ginsenosides on hepatic fibrosis and elucidate their underlying mechanistic pathways. This review aims to identify ginsenosides as potential therapeutic agents for hepatic fibrosis and establish a theoretical framework to support their clinical translation in the management of this condition. Introduction to ginsenosides Categorization of ginsenosides Ginsenosides, a class of triterpene saponins comprising an aglycone backbone with glycosyl substituents, are categorized by their aglycone moieties, this system defines three primary structural classes: dammarane-type (tetracyclic triterpenoids), ocotillol-type (tetracyclic triterpenoids), and oleanane-type (pentacyclic triterpenoids) [13]. Among these, dammarane-type ginsenosides represent the most abundant class and are further subdivided into protopanaxadiol (PPD)-type and protopanaxatriol (PPT)-type ginsenosides according to the position of glycosyl substitution. PPD-type ginsenosides possess glycosyl groups at C-3 and C-20, including ginsenosides Ra1-3, Rb1-3, Rc, Rd, Rg3, Rh2, and Rs1-2. And PPT-type ginsenosides feature glycosyl groups at the C-6 and C-20 positions, including ginsenosides Re, Rf, Rg1-2, and Rh1. Ocotillol-type ginsenosides share the same aglycone core structure as dammarane-type ginsenosides but are distinguished by a hydroxyisopropyl tetrahydrofuran substituent at C-20, such as ginsenosides Rh3, Ri, and Ro. In comparison, oleanane-type ginsenosides possess an oleanane-type aglycone scaffold, represented by ginsenosides F11, RT2, and RT5 [14,15]. Among these structural classes, only dammarane-type ginsenosides have been reported to show antifibrotic effects in hepatic fibrosis (Fig. 1).Fig. 1The classification and chemical structural formula of ginsenosides. (A) PPD-type ginsenosides. (B) PPT-type ginsenosides. (C) ocotillo-type ginsenosides. (D) oleanane acid-type ginsenosides. The classification and chemical structural formula of ginsenosides. (A) PPD-type ginsenosides. (B) PPT-type ginsenosides. (C) ocotillo-type ginsenosides. (D) oleanane acid-type ginsenosides. The structure-activity properties of ginsenosides The chemical structure of ginsenosides, including the count, identity, and position of sugar moieties, as well as the stereochemical configuration at C-20, is closely correlated with their pharmacological activities [16]. The number of glycosyl substituents demonstrates a positive correlation with anti-inflammatory activity but an inverse correlation with cytotoxic potency. Ginsenoside Rb1, bearing four sugar moieties, shows significantly greater anti-inflammatory effects in Alzheimer's disease models compared to ginsenoside Rg1, which contains two sugar moieties [17]. Ginsenosides Rb1 and Rb2, bearing four glycosyl substituents, showed significantly lower cytotoxicity compared to ginsenosides Rh2 and compound K (CK), which possess only a single sugar moiety [18]. Furthermore, the type of sugar moiety influences the antioxidant capacity of ginsenosides. Ginsenoside Rb2, featuring a heterodisaccharide glycosidic linkage (glucose-arabinose), demonstrates superior antioxidant activity relative to ginsenoside Rb1, which contains a homodimeric disaccharide linkage (glucose-glucose) [16]. The position of glycosyl substitution also modulates the pharmacological activities of ginsenosides. PPD-type ginsenosides, with glycosyl groups at C-3, potently inhibit Na+/K+-ATPase activity, whereas PPT-type ginsenosides, bearing sugar moieties at C-6, display minimal inhibitory effects on this enzyme [19]. Similarly, ginsenoside Rh2 (PPD-type) demonstrates significantly greater antitumor activity than ginsenoside Rh1 (PPT-type) [20]. These positional differences in activity may be attributed to steric hindrance imposed by sugar moieties at C-6, which impedes the binding of ginsenosides to their target proteins. Finally, the stereochemical configuration at C-20 critically influences the pharmacological activities of ginsenosides. Although both ginsenoside 20(R)-Rg3 and 20(S)-Rg3 stereoisomers suppress the growth and curb the motility of vascular smooth muscle cells, 20(S)-Rg3 represents significantly more potent inhibitory effects than 20(R)-Rg3 [21]. Safety profile of ginsenosides Given the broad spectrum of pharmacological activities shown by ginsenosides, their safety and toxicity profiles have attracted considerable research interest. However, systematic safety evaluations of ginsenosides remain limited. A subchronic toxicity assessment examining Korean red ginseng preparation in rats revealed no toxicologically significant alterations following 13 weeks of oral delivery at doses of 500, 1000, and 2000 mg/kg/day. Evaluated parameters included food consumption, absolute and relative organ weights, body weight, ophthalmological examinations, serum biochemistry, hematological indices, gross pathology, histopathological findings, and mortality, none of which showed treatment-related adverse effects [22]. In a subchronic toxicity study evaluating GBCK25, a fermented ginseng product containing multiple ginsenosides, oral delivery at doses of 250, 500, and 1000 mg/kg/day for 13 weeks did not produce toxicological alterations in rats [23]. However, several studies have indicated that prolonged, high-dose ginsenoside administration may induce toxicity. Treatment with a rare ginsenoside mixture (600 mg/kg) composed primarily of Rg3, Rg5, Rg6, Rh4, Rk1, and F4 for 90 days resulted in hepatic and intestinal inflammation as well as intestinal microbiota dysbiosis in rats. The serum concentrations of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) were also significantly elevated following treatment. These adverse effects were absent in rats administered lower doses of the rare ginsenoside mixture (60 and 200 mg/kg/day) for 90 days, suggesting dose-dependent toxicity [24]. Similarly, oral administration of ginsenoside CK at 120 mg/kg/day for 26 weeks induced significant hepatotoxicity and nephrotoxicity in male rats, characterized by increased relative liver and kidney weights, elevated serum ALT and ALP levels, and liver cell death. In comparison, administration of ginsenoside CK at 13 and 40 mg/kg/day for 26 weeks produced no toxicity in male rats, while doses of 13, 40, as well as 120 mg/kg/day for the same duration showed no toxicity in female rats [25]. These findings indicate that ginsenoside toxicity is not only dose-dependent but also sex-specific. Furthermore, acute oral administration of ginsenoside CK (8 g/kg, single dose) produced no toxic effects in rats, suggesting potential time-dependent toxicity [25]. The adverse effects of ginsenoside CK (120 mg/kg/day for 26 weeks) were ameliorated following a 4-week withdrawal period in male rats. Similarly, toxicity induced by ginsenoside CK (36 mg/kg/day) or Rg3 (60 mg/kg/day) for 26 weeks was attenuated after a 4-week recovery phase in Beagle dogs [26,27]. These observations suggest that low-dose ginsenoside-induced toxicity may be reversible. Notably, the safety of ginsenoside CK exhibited different results in different studies [25,27]. Ginsenoside CK showed sex-specific toxicity in mice (120 mg/kg/day, 26 weeks), but exhibit sex-independent toxicity in Beagle dogs (36 mg/kg/day, 26 weeks). The discrepancy might attribute to species variation. Overall, ginsenosides administration at low doses demonstrate favorable safety profiles with minimal or no toxicity, and the toxicity appears to be dose- and time-dependent, sex-specific, and generally reversible. However, prolonged administration at high doses exhibits significant hepatotoxicity and nephrotoxicity, which warrants careful monitoring for potential toxic effects. The elucidation of the toxicological mechanisms and establishment of safe dosing parameters and treatment durations are critical for the clinical translation of ginsenosides. The pharmacological mechanism of ginsenosides against hepatic fibrosis Hepatic fibrosis is defined by the pathological deposition of ECM components secreted by activated HSCs, leading to cirrhosis and potential hepatic failure [28]. Therefore, therapeutic strategies targeting suppression of HSC activation or induction of HSC death represent critical approaches for ameliorating liver fibrosis. The activation of HSCs is regulated through complex pathways including the TGF-β-SMAD signaling pathway, autophagy, oxidative stress, and metabolic reprogramming [29]. In addition, hepatocyte injury, liver inflammation, and intestinal microbiota dysbiosis are also the critical reasons activating HSCs [30]. Restraining HSC activation directly Suppressing the TGF-β-SMAD pathway TGF-β represents the principal cytokine mediating HSC activation through stimulation of the TGF-β receptor (TGFR), which promotes SMAD2/3 phosphorylation and the resulting generation of the SMAD2/3-SMAD4 multisubunit complex. This complex translocates into the nuclear compartment and induces transcriptional activation of genes associated with HSC activation [31]. However, SMAD7 functions as an inhibitor that suppresses the TGF-β-SMAD signaling cascade through competitively binding to the TGFR. Ginsenoside Rg1 upregulated SMAD7 expression by suppressing DNA methyltransferase (DNMT) 1-mediated SMAD7 methylation which induced SMAD7 ubiquitination and degradation. Subsequently, its inhibition of the TGF-β-SMAD pathway consequently led to the suppression of HSC activation, eventually ameliorating CCl4-induced hepatic fibrosis [32]. Furthermore, ginsenoside Rg1 was demonstrated to increase microRNA (miR)-152 expression, which targets DNMT1, hence reducing DNMT1 protein levels. Vitamin D (VD) plays the role of a suppressor for the TGF-β-SMAD pathway [33]. VD activates the VD receptor (VDR), promoting VDR-SMAD3 complex formation, preventing TGF-β-induced SMAD3 phosphorylation, and suppressing the transcription of SMAD3-mediated profibrogenic genes. Ginsenoside 25-hydroxy PPD (AD-2) was demonstrated to bind and activate VDR, which inhibits the TGF-β-SMAD pathway and ultimately attenuates lipopolysaccharide (LPS)-induced HSC activation and CCl4-triggered liver fibrosis [11]. Furthermore, ginsenoside 20S-PPD directly interact with the TGFR, suppressing HSC activation and hepatic fibrosis [34] (Fig.2).Fig. 2Ginsenosides alleviate liver fibrosis by suppressing HSC activation through multiple pathways. (1) Ginsenosides suppress HSC activation by attenuating TGF-β-SMAD signaling. ①Ginsenosides directly inhibit TGF-β binding to TGFR, therefore suppressing TGF-β-SMAD pathway activation. ②Ginsenosides upregulate miR-152 expression, which targets and suppresses DNMT1. Reduced DNMT1 decreases SMAD7 methylation, and thus inhibits SMAD7 ubiquitination and proteasomal degradation, ultimately preventing TGF-β-SMAD pathway activation. ③Ginsenosides bind to VDR and increase its interaction with SMAD3, which inhibits TGFR-mediated SMAD3 phosphorylation, leading to suppression of TGF-β-SMAD signaling. (2) Ginsenosides inhibit HSC activation through suppression of autophagy. Ginsenosides activate the PI3K-AKT-mTOR pathway to attenuate TGF-β- or LPS-induced HSC autophagy. (3) Ginsenosides inhibit HSC activation by mitigating oxidative stress. Ginsenosides suppress the activity of Keap1 which mediates Nrf2 ubiquitination and degradation, therefore increasing Nrf2 protein levels. Ginsenosides also inhibit SMAD2/3 phosphorylation which antagonizes Nrf2 activation. Increased Nrf2 levels and activation promote transcription of antioxidant enzymes, suppressing oxidative stress. (4) Ginsenosides inhibit HSC activation through modulation of cellular metabolism. Ginsenosides directly bind to GLS1 and LDHA and inhibit their activity, suppressing glutaminolysis and glycolysis, ultimately inducing HSC inactivation. Ginsenosides alleviate liver fibrosis by suppressing HSC activation through multiple pathways. (1) Ginsenosides suppress HSC activation by attenuating TGF-β-SMAD signaling. ①Ginsenosides directly inhibit TGF-β binding to TGFR, therefore suppressing TGF-β-SMAD pathway activation. ②Ginsenosides upregulate miR-152 expression, which targets and suppresses DNMT1. Reduced DNMT1 decreases SMAD7 methylation, and thus inhibits SMAD7 ubiquitination and proteasomal degradation, ultimately preventing TGF-β-SMAD pathway activation. ③Ginsenosides bind to VDR and increase its interaction with SMAD3, which inhibits TGFR-mediated SMAD3 phosphorylation, leading to suppression of TGF-β-SMAD signaling. (2) Ginsenosides inhibit HSC activation through suppression of autophagy. Ginsenosides activate the PI3K-AKT-mTOR pathway to attenuate TGF-β- or LPS-induced HSC autophagy. (3) Ginsenosides inhibit HSC activation by mitigating oxidative stress. Ginsenosides suppress the activity of Keap1 which mediates Nrf2 ubiquitination and degradation, therefore increasing Nrf2 protein levels. Ginsenosides also inhibit SMAD2/3 phosphorylation which antagonizes Nrf2 activation. Increased Nrf2 levels and activation promote transcription of antioxidant enzymes, suppressing oxidative stress. (4) Ginsenosides inhibit HSC activation through modulation of cellular metabolism. Ginsenosides directly bind to GLS1 and LDHA and inhibit their activity, suppressing glutaminolysis and glycolysis, ultimately inducing HSC inactivation. Inhibiting HSC autophagy Autophagy is an essential catabolic process involving lysosomal degradation of damaged organelles and macromolecular components, maintaining cellular homeostasis [35]. Autophagic flux is upregulated in activated HSCs, and autophagy accelerates the transition of quiescent HSCs to an activated phenotype through lipid droplet degradation [36]. Ginsenoside Rg3 exerts anti-fibrotic effects through autophagy inhibition [37]. Ginsenoside Rg3 suppressed LPS-triggered HSC activation in vitro, as evidenced by decreased p62 levels and reduced LC3b/LC3a ratio. Furthermore, it attenuated the appearance of activation markers in HSCs, notably α-smooth muscle actin (α-SMA) and TGF-β, in thioacetamide (TAA)-induced murine hepatic fibrosis. Ginsenoside Rg3 also elevated the phosphomodification of PI3K, AKT, and mTOR, whereas the PI3K inhibitor LY294002 and mTOR inhibitor rapamycin abrogated the repressive influence of ginsenoside Rg3 on HSC activation and autophagy. These findings demonstrate that ginsenoside Rg3 inhibits autophagy and suppresses HSC activation mediated by the activation of the PI3K-AKT-mTOR pathway (Fig.2). Improving HSC oxidative stress In activated HSCs, oxidative stress serves as a key driver. This condition, triggered by a disparity between ROS generation and scavenging, can be therapeutically targeted; its suppression abrogates the activation process [38]. Ginsenoside Rg1 reversed HSC activation and ameliorated hepatic fibrosis through attenuation of oxidative stress [39]. In vitro, ginsenoside Rg1 reversed TGF-β-induced HSC activation. The Ginsenoside Rg1 induced the nuclear translocation of Nrf2, a redistribution characterized by its accumulation within the nucleus and concurrent decrease in the cytoplasm, and reduced intracellular ROS accumulation. In vivo, ginsenoside Rg1 ameliorated liver fibrosis in CCl4-treated mice, characterized by decreased hepatic collagen deposition and decreased serum ALT and aspartate aminotransferase (AST) levels. Furthermore, ginsenoside Rg1 decreased levels of malondialdehyde which is positively associated with liver oxidative stress, and promoted the activity levels of a panel of antioxidant enzymes, including GPX, SOD, and CAT, demonstrating the beneficial effects of ginsenoside Rg1 on the antioxidant system [40].Ginsenoside Rg1 blocks the degradation of Nrf2, which is mediated by kelch-like ECH-associated protein-1 (Keap1) through direct interaction with Keap1, and promotes Nrf2 activation via suppressing the TGF-β-SMAD pathway [39,41] (Fig.2). Modulating HSC metabolic reprogramming Metabolic reprogramming refers to cellular adjustment of metabolic pathways and bioenergetic production modes in response to environmental alterations or to support specific biological functions [42]. HSC activation is accompanied by extensive metabolic reprogramming. Quiescent HSCs rely predominantly on mitochondrial oxidative phosphorylation for energy production. Upon activation, HSCs undergo transdifferentiation toward a myofibroblast-like phenotype characterized by metabolic shift toward glycolysis, glutaminolysis, and fatty acid β-oxidation, which satisfy the increased bioenergetic and biosynthetic demands [43]. Ginsenoside CK ameliorated hepatic fibrosis in mice triggered by CCl4, ligation of the bile duct, and methionine-choline-deficient (MCD) diet, characterized by diminished collagen deposition and downregulated α-SMA levels [44]. In vitro, ginsenoside CK induced HSC inactivation following TGF-β stimulation, decreased lactate production, and suppressed the expression of hexokinase 2 (HK2), PKM, and LDHA. Ginsenoside CK attenuates GLS1 and LDHA enzymatic activity through direct binding, inhibiting glutaminolysis and glycolysis, ultimately suppressing HSC activation. Metabolic reprogramming of HSCs represents a critical therapeutic target for hepatic fibrosis (Fig.2). Inducing HSC death directly Promoting HSC ferroptosis Ferroptosis is defined as a non-apoptotic, iron-driven programmed cell death pathway that differs mechanistically from necrosis and autophagy [45]. Emerging evidence indicates that targeting HSC ferroptosis constitutes a novel therapeutic strategy for ameliorating hepatic fibrosis [46,47]. Ginsenoside RK1 significantly attenuated liver fibrosis in CCl4-treated mice, accompanied by elevated hepatic Fe2+ levels [47]. In vitro, RNA sequencing analysis revealed that ginsenoside RK1 promoted HSC ferroptosis and suppressed HSC proliferation. Treatment with the ferroptosis inhibitor Lip-1 abrogated the antiproliferative effects of ginsenoside RK1 on HSCs, indicating that ferroptosis plays an essential role in ginsenoside RK1-mediated inhibition of HSC proliferation. Mechanistic investigations revealed that ginsenoside RK1 promotes HSC ferroptosis through activation of the HK2-ACSL4-LPCAT3-ALOX5 pathway. Ginsenoside RK1 binds to HK2, preventing its degradation induced by serine proteases. Elevated HK2 upregulates ACSL4 expression, increasing LPCAT3 and ALOX5 levels, ultimately inducing HSC ferroptosis. Ginsenoside Rg3 has also been shown to increase ACSL4 levels through inhibition of DNMT3B-mediated ACSL4 methylation, facilitating HSC ferroptosis [9]. Ginsenoside Rg3 upregulates miR-6945-3p expression, which targets and suppresses DNMT3B, leading to inhibition of DNMT3B-mediated ACSL4 methylation that promotes its ubiquitination and proteasomal degradation. The elevated ACSL4 levels initiate HSC ferroptosis and ameliorate hepatic fibrosis. Ginsenoside Rb1 has been demonstrated to reduce CCl4-triggered liver fibrosis through promotion of ferroptosis, accompanied by increased Beclin 1 (BECN1) expression [48]. BECN1 knockdown reversed the stimulative effects of ginsenoside Rb1 on HSC ferroptosis, and further investigations demonstrated that BECN1 directly interacts with SLC7A11, suppressing its activity and ultimately initiating HSC ferroptosis. Therefore, ginsenoside Rb1 increases BECN1 expression and its interaction with SLC7A11, an inhibitor of ferroptosis, thus inducing HSC ferroptosis and attenuating hepatic fibrosis. Ginsenoside Rh2 similarly promotes HSC ferroptosis and ameliorates fibrosis through SLC7A11 inhibition [10]. However, it augments interferon regulatory factor 1 (IRF1) recruitment to the SLC7A11 promoter, suppressing SLC7A11 transcription. In conclusion, promotion of HSC ferroptosis represents a critical mechanism underlying the antifibrotic effects of ginsenosides (Fig.3).Fig. 3Ginsenosides ameliorate hepatic fibrosis through induction of HSC death. (1) Ginsenosides phosphorylate LKB1 and thus activate the LKB1-AMPK signaling pathway, inducing HSC apoptosis. (2) Ginsenosides bind with HK2 to prevent its degradation by serine proteases (SP), promoting ACSL4 expression. Elevated ACSL4 increases LPCAT3 levels, which then upregulate ALOX5, ultimately triggering HSC ferroptosis. Ginsenosides also upregulate miR-6945-3p which suppresses DNMT3B expression, consequently inhibiting ACSL4 methylation that facilitates ACSL4 ubiquitination and degradation, and thus inducing HSC ferroptosis via upregulating LPCAT3 and ALOX5. Ginsenosides increase BECN1 expression which inhibits SLC7A11 activity through direct interaction, therefore leading to HSC ferroptosis. Furthermore, ginsenosides elevate IRF1 recruitment to the SLC7A11 promoter, suppressing SLC7A11 transcription and thus initiating HSC ferroptosis. Ginsenosides ameliorate hepatic fibrosis through induction of HSC death. (1) Ginsenosides phosphorylate LKB1 and thus activate the LKB1-AMPK signaling pathway, inducing HSC apoptosis. (2) Ginsenosides bind with HK2 to prevent its degradation by serine proteases (SP), promoting ACSL4 expression. Elevated ACSL4 increases LPCAT3 levels, which then upregulate ALOX5, ultimately triggering HSC ferroptosis. Ginsenosides also upregulate miR-6945-3p which suppresses DNMT3B expression, consequently inhibiting ACSL4 methylation that facilitates ACSL4 ubiquitination and degradation, and thus inducing HSC ferroptosis via upregulating LPCAT3 and ALOX5. Ginsenosides increase BECN1 expression which inhibits SLC7A11 activity through direct interaction, therefore leading to HSC ferroptosis. Furthermore, ginsenosides elevate IRF1 recruitment to the SLC7A11 promoter, suppressing SLC7A11 transcription and thus initiating HSC ferroptosis. Inducing HSC apoptosis Targeting the induction of apoptosis in HSCs represents a viable approach for treating hepatic fibrosis [49]. The aglycone metabolite of ginsenosides, 20S-PPD, reduced HSC viability in a concentration-dependent manner [50]. Annexin V-PI flow cytometric analysis demonstrated that 20S-PPD significantly increased the apoptotic fraction of HSCs. Furthermore,20S-PPD enhanced the levels of pro-apoptotic proteins, including BAX and cleaved PARP, while suppressed the anti-apoptotic protein BCL-2. Mechanistic investigations revealed that 20S-PPD enhanced AMPK phosphorylation in a dose-dependent fashion, and the AMPK suppressor compound C abrogated the cytotoxic effects of 20S-PPD on HSCs, indicating that 20S-PPD induces HSC apoptosis through AMPK phosphorylation. Furthermore, 20S-PPD induced the phosphorylation of liver kinase B1 (LKB1), an upstream kinase that activates AMPK, and LKB1 knockdown via siRNA transfection prevented 20S-PPD-induced HSC apoptosis and AMPK phosphorylation. 20S-PPD ameliorates hepatic fibrosis by promoting HSC apoptosis, which is achieved via its activation of the LKB1-AMPK signaling cascade (Fig.3). Attenuating hepatocyte injury Hepatocyte injury, the initiating event in hepatic fibrosis, can induce HSC activation directly or indirectly through the release of damage-associated mediators, including TGF-β, PDGF, and ROS, which then promote fibrogenesis [51]. Hence, attenuating hepatocyte injury represents an additional therapeutic strategy for ameliorating liver fibrosis. Recently, several ginsenosides have been reported to reduce hepatic fibrosis through inhibition of hepatocyte damage. Ginsenoside Rg5 ameliorated hepatocyte injury and liver fibrosis induced by a high-fat and high-cholesterol (HFHC) diet combined with CCl4 administration [52]. Ginsenoside Rg5 also prevented free fatty acid (FFA)-induced hepatocyte apoptosis and injury in vitro. Mechanistic studies revealed that ginsenoside Rg5 activated SIRT1, a critical regulator of liver injury, through direct binding, which followingly suppressed Notch-1 signaling [52,53]. SIRT1 activation by ginsenoside Rg5 inhibited Jagged-1-mediated Notch-1 activation through deacetylation of N1ICD, a transcription factor released from activated Notch-1. Deacetylated N1ICD failed to translocate into the nucleus, blocking Hes1 expression which promotes FFA-induced hepatocyte injury through upregulation of p53. Similarly, ginsenoside CK attenuated hepatic lipidosis and fibrosis in high-fat diet (HFD)-treated mice, potentially through reduction of lipotoxicity-mediated hepatocyte damage [54]. Ginsenoside CK ameliorates FFA-induced hepatocyte injury through inhibition of mTOR which suppresses fatty acid β-oxidation and accelerates lipogenesis. Ginsenoside Rg1 attenuated LPS-induced hepatic injury, inflammation, and fibrosis by mitigating hepatocyte damage [55]. In vitro, it protected hepatocytes from LPS-induced injury. Both in vitro and in vivo, ginsenoside Rg1 decreased Keap1 expression, increased HO-1 and phosphorylated Nrf2 levels, and promoted Nrf2 nuclear translocation. Inhibition of Nrf2 with ML385 reversed these protective effects, leading to elevated ROS production and proinflammatory cytokine expression. These findings indicate that ginsenoside Rg1 exerts its hepatoprotective effects primarily through activation of Nrf2 signaling. The combined reduction in ROS and proinflammatory cytokines synergistically mitigates LPS-induced hepatocellular damage. As a consequence, ginsenosides attenuate hepatocyte injury through modulation of multiple signaling pathways, including SIRT1-N1ICD-Hes1-p53, mTOR, and Keap1-Nrf2 pathways (Fig. 4).Fig. 4Ginsenosides attenuate liver fibrosis by alleviating hepatocyte injury. (1) Ginsenosides directly bind to and activate SIRT1, which catalyzes deacetylation of N1ICD and suppresses its transcriptional activity, leading to downregulation of Hes1 expression. Reduced Hes1 subsequently inhibits p53 expression, thereby ameliorating hepatocellular damage. (2) Ginsenosides elevate Nrf2 protein levels and promote antioxidant genes transcription through inhibition of Keap1 activity, attenuating ROS generation. Decreased ROS directly mitigates hepatocyte injury and also indirectly alleviate this injury by declining inflammatory cytokines. (3) Ginsenosides suppress mTOR activity, thereby promoting lipolysis and lipid secretion while inhibiting lipogenesis and lipid uptake. These metabolic effects reduce hepatocyte damage. Collectively, the inhibition of hepatocyte injury ultimately attenuates HSC activation. Ginsenosides attenuate liver fibrosis by alleviating hepatocyte injury. (1) Ginsenosides directly bind to and activate SIRT1, which catalyzes deacetylation of N1ICD and suppresses its transcriptional activity, leading to downregulation of Hes1 expression. Reduced Hes1 subsequently inhibits p53 expression, thereby ameliorating hepatocellular damage. (2) Ginsenosides elevate Nrf2 protein levels and promote antioxidant genes transcription through inhibition of Keap1 activity, attenuating ROS generation. Decreased ROS directly mitigates hepatocyte injury and also indirectly alleviate this injury by declining inflammatory cytokines. (3) Ginsenosides suppress mTOR activity, thereby promoting lipolysis and lipid secretion while inhibiting lipogenesis and lipid uptake. These metabolic effects reduce hepatocyte damage. Collectively, the inhibition of hepatocyte injury ultimately attenuates HSC activation. Attenuating liver inflammation Liver inflammation, predominantly arising from hepatocyte injury, represents a central driving factor in the progression of hepatic fibrosis, and then promotes HSC activation through the production of abundant inflammation-promoting molecules [56]. Several ginsenosides, notably Rg1, 25-OCH3-PPD, and Rd, show efficacy against fibrosis. This action is mediated by disrupting the assembly of the NLRP3 inflammasome, a complex that controls the activation and secretion of pro-inflammatory cytokines [[57], [58], [59]]. Ginsenoside Rg1 attenuated age-associated hepatic fibrosis by inhibiting NADPH oxidase (NOX) 4-dependent NLRP3 inflammasome activation [57]. Ginsenoside Rg1 administration reduced hepatic expression of collagen type IV and TGF-β1 in senescence-accelerated mouse prone 8 (SAMP8) mice, concomitant with downregulation of NOX4, a principal enzymatic source of ROS. The resultant attenuation of oxidative stress prevented NLRP3 inflammasome oligomerization, diminishing proinflammatory cytokine secretion and ultimately suppressing hepatic inflammation and fibrogenesis. Ginsenoside Rg1 also improved LPS-induced liver inflammation and fibrosis, with decreased NLRP3 inflammasome and Keap1 level and increased phosphorylated level of Nrf2. Notably, pharmacological inhibition of Nrf2 by ML385 reversed the suppressive effect of ginsenoside Rg1 on NLRP3 inflammasome activation [55]. Therefore, ginsenoside Rg1 also suppressed NLRP3 inflammasome activation to alleviate liver inflammation, which was mediated by Nrf2 activation. Similarly, ginsenoside 25-OCH3-PPD demonstrated hepatoprotective effects against TAA-triggered hepatic injury and fibrosis [58]. Compared with TAA-treated mice, ginsenoside 25-OCH3-PPD administration resulted in significantly reduced serum ALT and AST levels, indicating attenuation of TAA-induced hepatocellular injury. Ginsenoside 25-OCH3-PPD also suppressed the expression of profibrogenic factors, including α-SMA, type I collagen, and tissue inhibitor of metalloproteinase-1 (TIMP-1), while enhancing the expression of the fibrinolytic enzyme matrix metalloproteinase-13 (MMP-13), demonstrating amelioration of TAA-induced hepatic fibrosis. Concurrently, ginsenoside 25-OCH3-PPD reduced the expression and proteolytic liberation of active proinflammatory cytokines, including interleukin (IL)-1β and IL-18, in fibrotic liver tissue, accompanied by decreased NLRP3 inflammasome formation. Ginsenoside 25-OCH3-PPD downregulated the level of P2X7 purinoceptor (P2X7R) which facilitated NLRP3 inflammasome recruitment and activation through interaction with its scaffold protein, suppressing NLRP3 inflammasome-mediated production and secretion of mature IL-1β and IL-18. Furthermore, ginsenoside 25-OCH3-PPD enhanced liver X receptor (LXR) activity which attenuated the P2X7R-NLRP3 signaling axis and inhibited transcription of pro-IL-1β and pro-IL-18 [58,60,61]. Overall, ginsenoside 25-OCH3-PPD activated LXR signaling, suppressing pro-IL-1β and pro-IL-18 transcription and inhibiting P2X7R-mediated NLRP3 inflammasome activation and subsequent cytokine maturation. This reduced secretion of proinflammatory cytokines and diminished liver inflammation, ultimately attenuating liver fibrosis. Ginsenoside Rd similarly ameliorated TAA-triggered liver inflammation and fibrosis via suppression of the P2X7R-NLRP3 inflammasome pathway [59]. The administration of XCT-790, a selective estrogen-related receptor α (ERRα) antagonist, or siRNA targeting ERRα abrogated the inhibitory effects of ginsenoside Rd on P2X7R expression, NLRP3 inflammasome activation, and hepatic fibrosis, indicating that ginsenoside Rd downregulates P2X7R through ERRα activation rather than LXR-dependent mechanisms. Ginsenoside Re treatment also alleviated TAA-induced liver injury and inflammation by inhibiting NLRP3 inflammasome, with inhibited NLRP3 inflammasome and autophagy and decreased phosphorylated levels of PI3K, AKT, and mTOR. And LY294002, a PI3K inhibitor, and rapamycin, a mTOR inhibitor, partially reversed the suppressive roles of G-Re in autophagy and inflammation, indicating that ginsenoside Re alleviated liver inflammation by suppressing PI3K-AKT-mTOR pathway [62]. In addition to suppressing NLRP3 inflammasome, ginsenosides inhibited NF-κB pathway to attenuate liver inflammation. Ginsenoside Rg2 directly bond with Nrf2 to activate it, which inhibited NF-κB pathway activation and inflammatory factor transcription, and thus alleviated liver inflammation [63]. Therefore, ginsenosides alleviate liver inflammation via suppressing NLRP3 inflammasome activation mediated by inhibition of NOX4, P2X7R, or PI3K-AKT signaling pathways, and activation of Nrf2, and inhibiting NF-κB pathway via Nrf2 activation (Fig. 5).Fig. 5Ginsenosides suppress hepatic inflammation to prevent liver fibrosis. Ginsenosides attenuate NOX4 expression, thereby inhibiting NLRP3 inflammasome activation and subsequent cleavage of pro-IL-1β and pro-IL-18 into their mature forms. Additionally, ginsenosides suppress P2X7R-mediated inflammasome activation through the activation of ERRα and LXR. Activated LXR downregulates pro-inflammatory cytokine expression. Furthermore, ginsenosides activate the Keap1-Nrf2 pathway, which suppresses pro-inflammatory cytokine production via NF-κB pathway inhibition and prevents inflammasome activation by reducing ROS levels. These integrated effects collectively decrease cytokine production and suppress HSC activation, thereby attenuating hepatic fibrosis. Ginsenosides suppress hepatic inflammation to prevent liver fibrosis. Ginsenosides attenuate NOX4 expression, thereby inhibiting NLRP3 inflammasome activation and subsequent cleavage of pro-IL-1β and pro-IL-18 into their mature forms. Additionally, ginsenosides suppress P2X7R-mediated inflammasome activation through the activation of ERRα and LXR. Activated LXR downregulates pro-inflammatory cytokine expression. Furthermore, ginsenosides activate the Keap1-Nrf2 pathway, which suppresses pro-inflammatory cytokine production via NF-κB pathway inhibition and prevents inflammasome activation by reducing ROS levels. These integrated effects collectively decrease cytokine production and suppress HSC activation, thereby attenuating hepatic fibrosis. Regulating intestinal microbiota The intestinal microbiota represents a significant association with hepatic fibrosis progression, predominantly mediated through microbial metabolites and LPS [[64], [65], [66]]. Distinct microbial metabolites exert divergent effects on liver fibrosis. For example, short-chain fatty acids (SCFAs) and urolithin A demonstrate antifibrotic properties, whereas TMAO promotes fibrogenesis, with these effects mediated through modulation of hepatocyte injury, immunocyte function, and HSC activation [64,67,68]. LPS promotes immunocyte and HSC activation, exacerbating hepatic fibrosis [11,69]. Ginsenoside Rg1 has been extensively documented to ameliorate liver fibrosis [55,57]. Recently, evidence demonstrated that ginsenoside Rg1 modulated intestinal microbiota composition and elevated intestinal levels of several SCFAs, including acetate, propionate, and butyrate, which are produced by commensal bacteria and relay hepatic fibrosis progression [67,70]. Therefore, ginsenoside Rg1 potentially attenuates liver fibrosis in part through enrichment of SCFA-producing microbial populations. Different SCFAs produced by intestinal microbiota alleviated liver fibrosis via various mechanisms. Acetate suppressed hepatocyte death by activating the AMPK-SIRT1-PGC-1α axis, which indirectly inhibiting HSC activation [71]. In detail, acetate promote the phosphorylation and activation of the AMPK-SIRT1 axis in hepatocytes. Activated SIRT1 deacetylates PGC-1α, which inhibits PGC-1α degradation and promotes its activation, resulting in attenuated hepatocyte injury and further indirectly inhibiting HSC activation. Propionate inhibited HSC activation via stimulating Keap1-Nrf2 pathway [72]. And butyrate decreased miR-155-5p level which inhibited suppressor of cytokine signaling 1 (SOCS1) expression, thus lowering the production of platelet-derived growth factor (PDGF), a kind of pro-fibrotic factor, and eventually blocking HSC activation [73]. In addition, LPS decrease was reported to mediate the alleviated role of ginsenosides in liver fibrosis. LPS induces immunocytes to produce pro-inflammatory factors via activating TLR4-NF-κB pathway, which then stimulates HSC activation [74]. Also, LPS activates HSCs by promoting autophagy, which is mediated by AKT-mTOR and AMPK-ULK1 pathways [75]. Ginsenoside Rh2 has also been shown to ameliorate liver fibrosis triggered by choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), with mechanisms partially attributed to restoration of intestinal microbiota homeostasis and reduction of LPS levels [76]. Relative to CDAHFD-induced fibrotic mice, ginsenoside Rh2 supplementation suppressed hepatic lipid accumulation and fibrosis, ameliorated intestinal barrier dysfunction, modulated intestinal microbiota composition, and reduced serum LPS concentrations. The ginsenoside Rh2 attenuated LPS levels through restoration of intestinal microbiota balance while simultaneously inhibiting LPS-induced HSC activation via suppression of autophagy. Ginsenoside Rk3 also ameliorated liver fibrosis induced by combination of HFHC diet with CCl4 administration, with mechanisms partially involving modulation of intestinal microbiota [77]. Ginsenoside Rk3 administration attenuated hepatic inflammation, lipid accumulation, and fibrosis in model mice, accompanied by alterations in intestinal microbiota diversity and abundance. Compared with control mice, the Bacteroidetes/Firmicutes ratio was significantly reduced in model mice, and ginsenoside Rk3 reversed this dysbiosis, with increased Bacteroidetes and decreased Firmicutes abundance. As a consequence, ginsenosides ameliorate hepatic fibrosis through modulation of intestinal microbiota, resulting in decreased LPS levels and increased SCFA production (Fig. 6).Fig. 6Ginsenosides ameliorate liver fibrosis through modulation of the intestinal microbiota. (A) Ginsenosides reshape the gut microbiota composition by reducing Firmicutes and Proteobacteria abundance while increasing Bacteroidetes and SCFA-producing bacteria. These alterations decrease LPS production and elevate SCFA levels, thereby inhibiting HSC activation and attenuating liver fibrosis. (B) SCFAs promote phosphorylation and activation of the AMPK-SIRT1 axis in hepatocytes. Activated SIRT1 deacetylates PGC-1α, preventing its degradation and enhancing its activity, which attenuates hepatocyte injury and indirectly suppresses HSC activation. SCFAs also reduce miR-155-5p levels, thereby relieving suppression of cytokine signaling 1 (SOCS1) expression, consequently decreasing PDGF production and blocking HSC activation. Additionally, SCFAs inhibit HSC activation via stimulation of the Keap1-Nrf2 pathway. (C) LPS induces immunocytes to produce pro-inflammatory factors through TLR4-NF-κB pathway activation, thereby stimulating HSC activation. Moreover, LPS activates HSCs by promoting autophagy mediated through the AKT-mTOR and AMPK-ULK1 pathways. Ginsenosides ameliorate liver fibrosis through modulation of the intestinal microbiota. (A) Ginsenosides reshape the gut microbiota composition by reducing Firmicutes and Proteobacteria abundance while increasing Bacteroidetes and SCFA-producing bacteria. These alterations decrease LPS production and elevate SCFA levels, thereby inhibiting HSC activation and attenuating liver fibrosis. (B) SCFAs promote phosphorylation and activation of the AMPK-SIRT1 axis in hepatocytes. Activated SIRT1 deacetylates PGC-1α, preventing its degradation and enhancing its activity, which attenuates hepatocyte injury and indirectly suppresses HSC activation. SCFAs also reduce miR-155-5p levels, thereby relieving suppression of cytokine signaling 1 (SOCS1) expression, consequently decreasing PDGF production and blocking HSC activation. Additionally, SCFAs inhibit HSC activation via stimulation of the Keap1-Nrf2 pathway. (C) LPS induces immunocytes to produce pro-inflammatory factors through TLR4-NF-κB pathway activation, thereby stimulating HSC activation. Moreover, LPS activates HSCs by promoting autophagy mediated through the AKT-mTOR and AMPK-ULK1 pathways. Surprisingly, the same ginsenoside has been reported to exert anti-fibrotic effects via different mechanisms in various studies, which might arise from three reasons. First, the observed changes in certain signaling pathways were merely correlated with ginsenoside treatment in many studies, without rigorous evidence to confirm these pathways as the direct mechanisms underlying the amelioration of liver fibrosis. Second, multiple targets of ginsenosides might be another reason, which can be proved by which blocking a single signaling pathway alone does not fully reverse the effects of ginsenosides. Third, these studies employed different animal models, which may predispose to distinct target preferences. Conclusions and perspectives Hepatic fibrosis, characterized by excessive ECM accumulation, constitutes a frequent pathological outcome of chronic liver injury, leading to scar tissue formation and disrupted hepatic architecture [1]. Without therapeutic intervention, fibrosis may progress to liver failure and cancer. Reversing hepatic fibrosis is a critical therapeutic strategy to halt the advancement of chronic liver diseases towards liver failure and cancer. The pathological manifestations are associated with HSC activation, chronic hepatocyte injury, and liver inflammation, which are linked to intestinal microbiota dysbiosis. Activated HSCs undergo transdifferentiation into myofibroblast-like cells and synthesize excessive ECM, resulting in disruption of hepatic architecture [2,3]. However, resmetirom remains the only FDA-approved antifibrotic agent, with indications limited to patients with MASLD and demonstrating modest efficacy. Several compounds showing antifibrotic activity have also displayed significant toxicity. Therefore, there is a critical demand to develop safe and effective therapeutics for hepatic fibrosis. Given the multifactorial pathogenesis of liver fibrosis, antifibrotic agents targeting multiple pathways may represent a viable therapeutic approach. Accumulating evidence demonstrates that ginsenosides attenuate hepatic fibrosis through diverse mechanisms, suggesting their potential as antifibrotic therapeutics. In this review, we provide a concise introduction to ginsenosides and comprehensively summarize the mechanisms underlying their antifibrotic effects. Only PPD-type and PPT-type ginsenosides have been reported to ameliorate liver fibrosis. These compounds exert antifibrotic effects through suppression of HSC activation, induction of HSC apoptosis, attenuation of hepatocyte injury, inhibition of liver inflammation, and modulation of intestinal microbiota. Table 1 shows the anti-fibrotic effects and mechanisms of ginsenosides against liver fibrosis.Table 1Anti-fibrotic mechanisms of ginsenosides against liver fibrosis.Table 1GinsenosideClassificationAnimal ModelsMechanism of attenuating liver fibrosisRef.AD-2PPDCCl4-induced liver fibrosis mouse modelInhibiting HSC activation by suppressing the TGF-β-SMAD signaling pathway via binding with VDR.[11]CKPPDLiver fibrosis mouse model induced by CCl4, bile duct ligation, MCD, or HFD1. Suppressing HSC activation by regulating HSC metabolic reprogramming via inhibiting GLS1 and LDHA activity.2. Alleviating hepatocyte injury via inhibiting the mTOR pathway.[44,55]Rb1PPDCCl4-induced liver fibrosis mouse modelInducing HSC ferroptosis by inhibiting SLC7A11 activity via increasing BECN.[48]RdPPDTAA-induced liver fibrosis mouse modelAlleviating liver inflammation by suppressing P2X7R-NLRP3 inflammasome pathway via activating ERRα.[59]RePPTTAA-induced liver fibrosis mouse modelAlleviating liver inflammation by inhibiting NLRP3 inflammasome via suppressing the PI3K-AKT-mTOR pathway.[62]Rg1PPT1. CCl4- or LPS-induced liver fibrosis mouse model2. SAMP8 mice, a spontaneous aging-related liver fibrosis model1. Inhibiting HSC activation by suppressing the TGF-β-SMAD pathway via increasing SMAD7, and ameliorating HSC oxidative stress via activating Keap1-Nrf2 pathway.2. Alleviating hepatocyte injury via activating Keap1-Nrf2 pathway.3. Alleviating liver inflammation by suppressing NLRP3 inflammasome via inhibiting NOX4 and activating Keap1-Nrf2 pathway.4. Increasing SCFA-producing gut microbiota.[32,[39], [40], [41],55,57,67,70]Rg2PPTLiver fibrosis mouse model induced by MCD dietAlleviating liver inflammation by inhibiting the NF-κB pathway via directly binding with and activating Nrf2.[63]Rg3PPDTAA- or CCl4-induced liver fibrosis mouse model1. Inhibiting HSC activation by suppressing HSC autophagy via activating PI3K-AKT-mTOR pathway.2. Promoting HSC ferroptosis by upregulating ACSL4 via increasing miR-6945-3p which targeted DNMT3B.[9,37]Rg5PPDLiver fibrosis mouse model induced by the combination of HFHC diet with CCl4Alleviating hepatocyte injury via activating SIRT1 and inhibiting Notch1 signaling pathway.[52,53]Rh2PPDCCl4- or CDAHFD-induced liver fibrosis mouse model1. Promoting HSC ferroptosis by inhibiting SLC7A11 transcription via enhancing IRF1 binding with SLC7A11 promoter.2. Modulating the gut microbiota and reducing LPS levels.[10,76]Rk1PPDCCl4-induced liver fibrosis mouse modelPromoting HSC ferroptosis via activating HK2-ACSL4-LPCAT3-ALOX5 pathway.[47]Rk3PPTLiver fibrosis mouse model induced by the combination of HFHC diet with CCl4Regulating intestinal microbiota.[77]20S-PPDPPDNo animal modelInducing HSC apoptosis via activating LKB1-AMPK pathway.[50]25-OCH3-PPDPPDTAA-induced liver fibrosis mouse model1. Inhibiting HSC activation by suppressing TGF-β-SMAD pathway via binding with TGFR directly2. Alleviating liver inflammation by inhibiting P2X7R-NLRP3 inflammasome pathway via activating LXR.[34,58,60,61] Table 1Anti-fibrotic mechanisms of ginsenosides against liver fibrosis.Table 1GinsenosideClassificationAnimal ModelsMechanism of attenuating liver fibrosisRef.AD-2PPDCCl4-induced liver fibrosis mouse modelInhibiting HSC activation by suppressing the TGF-β-SMAD signaling pathway via binding with VDR.[11]CKPPDLiver fibrosis mouse model induced by CCl4, bile duct ligation, MCD, or HFD1. Suppressing HSC activation by regulating HSC metabolic reprogramming via inhibiting GLS1 and LDHA activity.2. Alleviating hepatocyte injury via inhibiting the mTOR pathway.[44,55]Rb1PPDCCl4-induced liver fibrosis mouse modelInducing HSC ferroptosis by inhibiting SLC7A11 activity via increasing BECN.[48]RdPPDTAA-induced liver fibrosis mouse modelAlleviating liver inflammation by suppressing P2X7R-NLRP3 inflammasome pathway via activating ERRα.[59]RePPTTAA-induced liver fibrosis mouse modelAlleviating liver inflammation by inhibiting NLRP3 inflammasome via suppressing the PI3K-AKT-mTOR pathway.[62]Rg1PPT1. CCl4- or LPS-induced liver fibrosis mouse model2. SAMP8 mice, a spontaneous aging-related liver fibrosis model1. Inhibiting HSC activation by suppressing the TGF-β-SMAD pathway via increasing SMAD7, and ameliorating HSC oxidative stress via activating Keap1-Nrf2 pathway.2. Alleviating hepatocyte injury via activating Keap1-Nrf2 pathway.3. Alleviating liver inflammation by suppressing NLRP3 inflammasome via inhibiting NOX4 and activating Keap1-Nrf2 pathway.4. Increasing SCFA-producing gut microbiota.[32,[39], [40], [41],55,57,67,70]Rg2PPTLiver fibrosis mouse model induced by MCD dietAlleviating liver inflammation by inhibiting the NF-κB pathway via directly binding with and activating Nrf2.[63]Rg3PPDTAA- or CCl4-induced liver fibrosis mouse model1. Inhibiting HSC activation by suppressing HSC autophagy via activating PI3K-AKT-mTOR pathway.2. Promoting HSC ferroptosis by upregulating ACSL4 via increasing miR-6945-3p which targeted DNMT3B.[9,37]Rg5PPDLiver fibrosis mouse model induced by the combination of HFHC diet with CCl4Alleviating hepatocyte injury via activating SIRT1 and inhibiting Notch1 signaling pathway.[52,53]Rh2PPDCCl4- or CDAHFD-induced liver fibrosis mouse model1. Promoting HSC ferroptosis by inhibiting SLC7A11 transcription via enhancing IRF1 binding with SLC7A11 promoter.2. Modulating the gut microbiota and reducing LPS levels.[10,76]Rk1PPDCCl4-induced liver fibrosis mouse modelPromoting HSC ferroptosis via activating HK2-ACSL4-LPCAT3-ALOX5 pathway.[47]Rk3PPTLiver fibrosis mouse model induced by the combination of HFHC diet with CCl4Regulating intestinal microbiota.[77]20S-PPDPPDNo animal modelInducing HSC apoptosis via activating LKB1-AMPK pathway.[50]25-OCH3-PPDPPDTAA-induced liver fibrosis mouse model1. Inhibiting HSC activation by suppressing TGF-β-SMAD pathway via binding with TGFR directly2. Alleviating liver inflammation by inhibiting P2X7R-NLRP3 inflammasome pathway via activating LXR.[34,58,60,61] Anti-fibrotic mechanisms of ginsenosides against liver fibrosis. Despite extensive research on the anti-fibrotic effects of ginsenosides in liver fibrosis, direct comparative studies on their efficacy remain scarce. Nevertheless, emerging evidence permits a preliminary comparative analysis based on the number of studies and the types of animal models employed. A total of four ginsenosides have demonstrated efficacy against liver fibrosis in at least two studies and two animal models, including ginsenosides CK, Rg1, Rg3, and Rh2. Among them, ginsenoside CK has demonstrated anti-fibrotic activity in four animal models, including CCl4-, MCD-, HFD-, and bile duct ligation-induced models, whereas ginsenoside Rg1, although active in three animal models, has been the most extensively reported in the literature. These evidences indicate that ginsenoside CK and Rg1 might exert most robust and reproducible effects against liver fibrosis. However, ginsenoside CK exhibit a narrow therapeutic window (30-120 mg/kg) and poor bioavailability (<1%) [25,44,54]. In addition, the pathogenesis of liver fibrosis is multifactorial and complex, and ginsenoside Rg1 were found to alleviate liver fibrosis by directly inhibiting HSC activation, attenuating hepatocyte damage, suppressing inflammation, and modulating intestinal microbiota. Therefore, ginsenoside Rg1 might exert robust and reproducible effect on liver fibrosis. It is noteworthy that the structure of ginsenosides is strongly associated with their activities. The number of glycosyl substituents is positively correlated with anti-inflammatory activity but inversely correlated with cytotoxic potency, which demonstrate increasing glycosyl substituents of ginsenosides potentially enhances their effects against liver fibrosis and decreases their toxicity. Furthermore, a heterodisaccharide glycosidic linkage exhibit superior antioxidant activity compared with a homodimeric disaccharide linkage, which shows potential anti-fibrotic activity. Consequently, increasing glycosyl substituents and replacing with heterodisaccharide glycosidic linkages might strengthen the anti-fibrotic activities of ginsenosides and lower their toxicity. Notably, many mechanisms were reported to involve in the alleviated effects of ginsenosides on liver fibrosis, there is no FDA-approved anti-liver fibrosis drug targeting these mechanisms. That might be attributed to the complex pathogenesis of liver fibrosis, and targeting multiple mechanisms is the potential therapeutic strategy. Despite significant preclinical evidence, clinical data supporting the antifibrotic efficacy of ginsenosides remain scarce. This gap can be attributed to several fundamental challenges. First, the pharmacokinetic properties of ginsenosides are inherently unfavorable for oral dosing. Most ginsenosides exhibit extremely low oral bioavailability (typically <15%) due to poor aqueous solubility, limited intestinal permeability, and extensive first-pass metabolism [78,79]. The advancement of drug delivery systems, including liposomes, microspheres, and hydrogels, may elevate their bioavailability and antifibrotic efficacy. Second, ginsenosides are extensively metabolized by intestinal microbiota to generate active metabolites, which introduces unpredictable individual variability [79]. The composition of gut microbiota varies significantly across individuals due to diet, genetics, and disease status, leading to inconsistent systemic exposure of ginsenosides and making it difficult to establish standardized dosing regimens. Third, preclinical evidence is overreliant on chemically induced fibrosis models. The vast majority of studies used CCl4 or TAA-induced fibrosis models that imperfectly recapitulates human liver fibrosis. Therefore, robust preclinical evidence from diverse animal models, such as diet- or bile duct ligation-induced liver fibrosis, is imperative for the clinical translation of ginsenosides. Fourth, the effective dose in humans cannot be directly extrapolated from that in animals. Most preclinical studies use doses ranging from 10 to 100 mg/kg in rodents. Given standard allometric scaling based on body surface area, a dose of 20 mg/kg in rats translates to approximately 224 mg for a 70 kg adult, a dose that falls within the range associated with toxicity in 26-week animal studies. Fifth, liver fibrosis necessitates long-term pharmacotherapy, yet there is paucity of long-term safety studies. The maximum duration of existing safety data is only 26 weeks, and long-term treatment with ginsenosides exert toxicity. Furthermore, the underlying toxicological mechanisms and parameters for safe dosing and duration remain undefined. Elucidating these mechanisms and establishing safe administration protocols are essential prerequisites for clinical translation of ginsenosides. Notably, some ginsenosides exhibit a narrow therapeutic window and gender-dependent toxicity. Given these challenges, the clinical application of ginsenosides in the treatment of liver fibrosis is a promising but arduous process, which requires the collaborative efforts of multiple disciplines to achieve. Nevertheless, this review lays the groundwork for developing new antifibrotic drugs and broadening the clinical use of ginsenosides, while also shedding light on strategies for managing liver fibrosis in clinical practice. CRediT authorship contribution statement Zhengzheng Wu: Conceptualization, writing, and original draft. Yi Liu: Funding acquisition, reviewing, and editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.